Skip to main content

Market Overview

Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial

Share:
Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial
  • Protagonist Therapeutics Inc (NASDAQ: PTGXhas announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a type of blood cancer.
  • Data were presented at the European Hematology Association 2021 Virtual Congress.
  • Rusfertide demonstrated long-term control of hematocrit (proportion of red blood cells in the blood) and durability of effect based on patients treated up to 18 months.
  • The treatment led to a reversal of iron deficiency as evidenced by increasing serum ferritin, mean corpuscular volume, and mean corpuscular hemoglobin values.
  • Rusfertide demonstrated similar efficacy in all patients, independent of risk group or prior and concurrent therapy.
  • Benefits were observed in patient-reported outcomes, attributed mainly to fatigue, concentration, consistent with an improvement in iron deficiency.
  • The current data indicate that rusfertide is well tolerated. The most common adverse events observed were transient injection site reactions.
  • The company will start the Phase 3 trial of rusfertide in early 2022.
  • Price Action: PTGX shares are up 17% at $39.59 during the market session on the last check Friday.
 

Related Articles (PTGX)

View Comments and Join the Discussion!

Posted-In: blood cancer Briefs Phase 2 TrialBiotech News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com